RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant

Enrolling by invitation · Early Phase 1

Conditions studied: Lung Transplant; Complications

In brief

The purpose of this study is to assess whether TNFa antibody use before lung transplant can prevent kidney injury after lung transplant.

Key facts

Study ID

NCT05950724

Run by

Northwestern University

People needed

20

Starts

2023-09-17

Expected to finish

2027-12-01

Last updated by the study team

2026-02-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Planning to undergo transplantation of the lung at Northwestern Memorial Hospital.
• Willing and able to read, understand, and be capable of giving informed consent.

You may not qualify if…

• Previous or current use of TNFa antibody.
• Positive virtual or retrospective crossmatch or highly sensitized (pRA > 30%) recipients.
• Any condition that, in the opinion of the attending physician, would place the patient at undue risk by participating.

Where it is running

• Northwestern University — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.